"Complete Response" Reg Seeks Comment On Public Disclosure Of NDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
The proposed rule would allow FDA to disclose the existence of an application once the sponsor has publicly disclosed it or after issuance of an approval or tentative approvable letter. The rule eliminates the use of "approvable" and "not approvable" letters.
You may also be interested in...
FDA Rejects “Approvable” And “Not Approvable” Letters
Agency will begin Aug. 11 to use “complete response” letters instead.
FDA Rejects “Approvable” And “Not Approvable” Letters
Agency will begin Aug. 11 to use “complete response” letters instead.
FDA 2004 Reg Agenda Includes "Complete Response" Rule, Electronic Drug Listing
The regulatory plan also states that a proposed rule on treatment use of investigational drugs is scheduled for October. A guidance on pregnancy labeling is planned for 2005.